Glenmark Pharmaceuticals’ arm receives $ 4 million from Forest Laboratories

25 Mar 2014 Evaluate

Glenmark Pharmaceuticals through its Swiss Subsidiary has received $ 4 million as research fee payment from Forest Laboratories on collaboration for the development of novel mPGES-1 inhibitors to treat chronic inflammatory conditions, including pain.

Under the terms of the agreement signed in FY 2012-13, Forest made$ 6 million upfront payment and also provided an additional $ 3 million to support the next phase of work. In September 2013, Glenmark received an additional amount of $ 2million as research fee payment from Forest Laboratories. Hence, the total amount received by Glenmark from Forest Laboratories  towards its novel mPEGS-1 inhibitors program is $ 15 million.

Glenmark’s current portfolio consists of 90 products authorized for distribution in the US marketplace and 53 ANDA’s pending approval with the USFDA. In addition to these internal Filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.

Glenmark Pharma Share Price

1540.70 -52.20 (-3.28%)
10-Jan-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1786.05
Dr. Reddys Lab 1354.20
Cipla 1470.05
Lupin 2190.50
Zydus Lifesciences 1004.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.